Field Medical Closes Oversubscribed $35 Million Series B to Advance Development of FieldForce™ Pulsed Field Ablation Platform

Field Medical, a clinical-stage company developing pulsed field ablation technology for cardiac arrhythmias, closed a $35 million Series B financing round co-led by BioStar Capital and Cue Growth, with participation from existing strategic investors. The funds will support the initiation of the pivotal VERITAS trial and further development of the FieldForce Ablation System.